Patents by Inventor Stewart Lyman

Stewart Lyman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • MODIFIED HUMAN THYMIC STROMAL LYMPHOPOIETIN
    Publication number: 20070218523
    Abstract: Modified, furin resistant human TSLP polypeptides and polynucleotides encoding the modified human TSLP polypeptides are provided. Pharmaceutical compositions, B and T cell activation agents, assays and methods of use are also described.
    Type: Application
    Filed: July 23, 2002
    Publication date: September 20, 2007
    Inventors: Stewart Lyman, Kirk Van Ness, Raymond Paxton
  • Methods of using flt3-ligand in the treatment of cancer
    Publication number: 20070207164
    Abstract: Ligands for flt3 receptors capable of transducing self-renewal signals to regulate the growth, proliferation or differentiation of progenitor cells and stem cells are disclosed. The invention is directed to Flt3-ligand as an isolated protein, the DNA encoding the Flt3-ligand, host cells transfected with cDNAs encoding Flt3-ligand, compositions comprising Flt3-ligand and methods of using Flt3-ligand in hematopoietic cell transplantation.
    Type: Application
    Filed: June 8, 2006
    Publication date: September 6, 2007
    Inventors: Stewart Lyman, M. Beckmann
  • Human TSLP polynucleotides
    Publication number: 20060223754
    Abstract: The invention is directed to purified and isolated novel TSLP polypeptides, the nucleic acids encoding such polypeptides, processes for production of recombinant forms of such polypeptides, antibodies generated against these polypeptides, fragmented peptides derived from these polypeptides, and the uses of the above.
    Type: Application
    Filed: June 13, 2006
    Publication date: October 5, 2006
    Applicant: Immunex Corporation
    Inventors: John Sims, Stewart Lyman, Hilary McKenna, Allison Armstrong
  • Flk-1 binding protein
    Publication number: 20060014252
    Abstract: A protein designated flk-1bp binds the vascular endothelial cell surface receptor flk-1. Isolated DNA encoding flk-1bp is provided, along with expression vectors and transformed host cells useful in producing flk-1bp polypeptides. Antibodies that are immunoreactive with flk-1bp are generated using the polypeptides disclosed herein.
    Type: Application
    Filed: September 14, 2005
    Publication date: January 19, 2006
    Applicant: Immunex Corporation
    Inventor: Stewart Lyman
  • Methods of using Flt3-Ligand in hematopoietic cell transplantation procedures incorporating nonmyeloablative conditioning regimens
    Publication number: 20050058622
    Abstract: The invention is directed to methods of using Flt3-Ligand in hematopoietic cell transplantation procedures using nonmyeloablative conditioning regimens. This abstract is provided for the sole purpose of enabling the reader to quickly ascertain the subject matter of the technical disclosure and is not intended to be used to interpret or limit the scope or meaning of the claims.
    Type: Application
    Filed: December 8, 2003
    Publication date: March 17, 2005
    Inventors: Stewart Lyman, M. Beckmann, Hilary McKenna, Richard Nash
  • Methods for using elk-L to enhance neuronal survival
    Patent number: 6540992
    Abstract: Elk ligand (Elk-L) polypeptides as well as DNA sequences, vectors and transformed host cells useful in providing elk-L polypeptides are used in methods for enhancing the survival or inhibiting the death of neurons, particularly hippocampal neurons. The elk-L polypeptides bind to a cell surface receptor that is a member of the tyrosine kinase receptor family.
    Type: Grant
    Filed: March 16, 1998
    Date of Patent: April 1, 2003
    Assignee: Genentech, Inc.
    Inventors: Stewart Lyman, M. Patricia Beckmann, Peter R. Baum, Melissa K. Carpenter
  • Antibodies directed against elk ligand
    Patent number: 5728813
    Abstract: Antibodies to elk ligand (elk-L) polypeptides as well as DNA sequences, vectors and transformed host cells useful in providing elk-L polypeptides. The elk-L polypeptide binds to a cell surface receptor that is a member of the tyrosine kinase receptor family.
    Type: Grant
    Filed: November 12, 1996
    Date of Patent: March 17, 1998
    Assignee: Immunex Corporation
    Inventors: Stewart Lyman, M. Patricia Beckmann, Peter R. Baum
  • Elk ligand fusion proteins
    Patent number: 5670625
    Abstract: elk ligand (elk-L) polypeptides as well as DNA sequences, vectors and transformed host cells useful in providing elk-L polypeptides. The elk-L polypeptide binds to a cell surface receptor that is a member of the tyrosine kinase receptor family.
    Type: Grant
    Filed: June 2, 1995
    Date of Patent: September 23, 1997
    Assignee: Immunex Corporation
    Inventors: Stewart Lyman, M. Patricia Beckmann, Peter R. Baum
  • Cytokine designated elk ligand
    Patent number: 5627267
    Abstract: elk ligand (elk-L) polypeptides as well as DNA sequences, vectors and transformed host cells useful in providing elk-L polypeptides. The elk-L polypeptide binds to a cell surface receptor that is a member of the tyrosine kinase receptor family.
    Type: Grant
    Filed: June 1, 1995
    Date of Patent: May 6, 1997
    Assignee: Immunex Corporation
    Inventors: Stewart Lyman, M. Patricia Beckmann, Peter R. Baum
  • Cytokine designated elk ligand
    Patent number: 5512457
    Abstract: elk ligand (elk-L) polypeptides as well as DNA sequences, vectors and transformed host cells useful in providing elk-L polypeptides. The elk-L polypeptide binds to a cell surface receptor that is a member of the tyrosine kinase receptor family.
    Type: Grant
    Filed: March 15, 1994
    Date of Patent: April 30, 1996
    Assignee: Immunex Corporation
    Inventors: Stewart Lyman, M. Patricia Beckmann, Peter R. Baum, Melissa K. Carpenter